A definite case of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) induced by administration of the Pfizer/BioNTech BNT162b2 vaccine for SARS-CoV2

At the end of December 2020, the anti-SARS-CoV2 vaccination campaign began in Italy1. As the number of vaccinated subjects in the general population has increased, several adverse reactions have been observed and reported, some more frequent, such as hyperpyrexia, lymphadenopathy, headache, or muscular-articular pain, and others rarer2. In this regard, the Italian pharmacovigilance agency (AIFA) plays a key role in monitoring adverse reactions to these vaccines2. Among the interregional pharmacovigilance projects promoted by AIFA, GRESIF (multiregional pharmacovigilance project "Severe systemic drug hypersensitivity reactions") has the task of detecting and analyzing severe cutaneous adverse reactions (SCARs) induced by drugs or vaccines3.
Source: Clinics in Dermatology - Category: Dermatology Authors: Tags: COVID-19: Important updates and developments Source Type: research